NCT05682950CompletedPhase 2
Optimal Margin Evaluation of Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer
A Prospective Study to Evaluate Optimal Margin of Iterative Cone-beam Computed Tomography Guided Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer
Source: ClinicalTrials.gov · Last updated 8 Jun 2026
Brief summary (registry, in English)
Online adaptive radiotherapy has demonstrated to be feasible to reduce inter-fractional radiotherapy errors as it re-optimizes treatment plan every fraction. To investigate the extent and value of margin reduction，we conduct a prospective clinical trial to determine the optimal margin and toxicity of smaller margin.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- First submitted
- 14 Dec 2022
- Start date
- 12 Sept 2022
- Primary completion date
- 6 Feb 2023
- Lead sponsor
- Peking Union Medical College Hospital
- Diseases
- Cervical cancer
- NCT number
- NCT05682950
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 15
- From 12 Sept 2022 to the primary completion date, 6 Feb 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subjects who have received prior pelvic radiotherapy.
- Subjects with contraindications to radiotherapy, as determined by the investigators.
Other illness
- Subjects with other primary malignancies.
- Any severe disease which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control, and emotional disturbance.
- Active infection with fever.
- Active inflammatory bowel disease.
Who the study is looking for
- Patients must be informed of the investigational nature of this study and give written informed consent before treatment.
- Postoperative endometrial and cervical cancer patients with pathologically confirmed no residual tumor at the resection margin and no evidence of distant metastasis (FIGO stage IVB).
- Pathological findings indicate risk factors and adjuvant radiotherapy are prescribe.
- Karnofsky score ≥ 70.
- Subjects aged ≥ 18 years and ≤ 70 years.
- No evidence of para-aortic metastatic lymph nodes.
- No contraindications to CT scanning.
- Subjects must be able to cooperate in completing the entire study.
- Adequate marrow: neutrophile granulocyte count ≥1.5\*10\^9/L, hemoglobin ≥ 80 g/L, platelet count ≥100\*10\^9/L.
- Normal liver and kidney function: Creatinine (Cr) \< 1.5 mg/dl, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) \< 2\*upper limit of normal (ULN).
Age in the registry: 18 years to 70 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking Union Medical College Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.